{"id":78513,"date":"2026-09-03T17:10:19","date_gmt":"2026-09-03T09:10:19","guid":{"rendered":"https:\/\/flcube.com\/?p=78513"},"modified":"2026-09-03T17:10:20","modified_gmt":"2026-09-03T09:10:20","slug":"ocumension-completes-enrollment-in-china-phase-iii-trial-of-ot-211-for-dry-eye-disease-aligned-with-global-comet-pivotal-program","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=78513","title":{"rendered":"Ocumension Completes Enrollment in China Phase III Trial of OT\u2011211 for Dry Eye Disease, Aligned with Global COMET Pivotal Program"},"content":{"rendered":"\n

Ocumension Therapeutics<\/strong> (HKG: 1477<\/a>) announced that all subjects have been enrolled as scheduled in the Chinese Phase III clinical trial of OT\u2011211<\/strong> (TRYPTYR, acotremon ophthalmic solution), a novel therapy for dry eye disease<\/strong>. The milestone keeps the China registrational program of OT\u2011211<\/strong> \u2014 the world’s first TRPM8 receptor agonist approved for dry eye disease<\/strong>, introduced into China under a strategic partnership between Ocumension<\/strong> and Alcon<\/strong> \u2014 on track with the asset’s global pivotal studies.<\/p>\n\n\n\n

Trial Design \u2013 China Phase III Study of OT\u2011211<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Phase \/ Design<\/td>Phase III, randomized, double\u2011blind, vehicle\u2011controlled, parallel\u2011group, multicenter study<\/td><\/tr>
Enrollment<\/td>398 subjects with moderate\u2011to\u2011severe dry eye disease<\/strong> (fully enrolled as scheduled)<\/td><\/tr>
Primary Endpoint<\/td>Proportion of subjects with an increase of \u226510 mm from baseline in unanesthetized Schirmer’s test score at Day 14<\/td><\/tr>
Endpoint Alignment<\/td>Consistent with the primary endpoints of OT\u2011211’s<\/strong> global pivotal Phase III trials (COMET\u20112 and COMET\u20113)<\/td><\/tr>
Status<\/td>Enrollment complete; efficacy and safety evaluation ongoing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Mechanism of Action<\/h2>\n\n\n\n